Cargando…
Can leukocyte telomere shortening be a possible biomarker to track Huntington’s disease progression?
Autores principales: | Mantuano, Elide, Peconi, Martina, Scarabino, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585568/ https://www.ncbi.nlm.nih.gov/pubmed/31169183 http://dx.doi.org/10.4103/1673-5374.257522 |
Ejemplares similares
-
Leukocyte Telomere Length as Potential Biomarker of HD Progression: A Follow-Up Study
por: Scarabino, Daniela, et al.
Publicado: (2022) -
Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer’s disease: new biomarkers for diagnosis and disease progression?
por: Corbo, Rosa Maria, et al.
Publicado: (2020) -
Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases
por: Scarabino, Daniela, et al.
Publicado: (2022) -
Analysis of the Association Between TERC and TERT Genetic Variation and Leukocyte Telomere Length and Human Lifespan—A Follow-Up Study
por: Scarabino, Daniela, et al.
Publicado: (2019) -
Circulating U13 Small Nucleolar RNA as a Potential Biomarker in Huntington’s Disease: A Pilot Study
por: Romano, Silvia, et al.
Publicado: (2022)